2010

2010 INTERCEPT Conference Abstracts

 

Jump to Conference
IHS ISBT & DGTI AABB
SIMTI ICEID  
SETS Workshop on XMRV  

 

International Haemovigilance Seminar (IHS)
February 17 - 19, 2010 | Dubrovnik, Croatia

  • Cazenave JP, Kientz D, Mendel I et al. Hemovigilance Surveillance Of Platelet Components Prepared With Pathogen Inactivation Treatment During a Three Year Period.
    [Abstract PDF]
      [Poster PDF]
     
  • Cazenave JP, Osselaer JC, Liu W et al. An Active Hemovigilance Program to Assess the Safety Outcome for 32, 480 INTERCEPT Plasma Component Transfusions.
    [Poster PDF]
     
  • Domanovic D, Milojkovic A, Cukjati M et al.  Hemovigilance of Transfusions with Platelet Treated with INTERCEPT Blood System Using an Active Hemovigilance Program - Data from Slovenia.
    [Abstract PDF]
     
  • Knutson F, Lof H.  HV at a University Hospital After Transfusions of Platelets Pathogen Inactivated with the INTERCEPT Technology.
    [Abstract PDF]
     
  • Osselaer JC, Cazenave JP, Liu W et al.  An Active Hemovigilance Program to Assess the Safety Outcome for 18,641 Platelet Components Tranfused in Multiple European Clinical Sites.
    [Abstract PDF]
     
  • Osselaer JC, De Coene B, Thonet MC et al. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components: A Six-year Hemovigilance Survey.
    [Poster PDF]

XXXIX Convegno Nazionale Di Studi Di Medicina Trasfusionale (SIMTI)

  • Furlo G, Stilo C, Attina A et al.  CMV e Trattamento Fotochimico dei Concentrati Piastrinici:  Impatto Clinico sui Pazienti Onco-Ematologici.  Esperienza del Sit di Reggio Calabria.
     
  • Ostuni A, Musaro A, Morciano MR et al.  Fotoinattivazione di Emocomponenti:  Impatto Qualitativo, Organizzativo ed Economico.

Socidad Espanola de Transfusion Sanguinea y Terapia Celular (SETS)

  • Yanez Izquierdo M.  Calidad del Plasma Inactivado con INTERCEPT Blood System, en Distintos Momentos de Inactivacion/Almacenaniento.
     
  • Yanez Izquierdo M.  Estudio Comparativo de Dos Metodos de Inactivacion de Plasma Resco Congelado.

XXXIst International Congress of the International Society of Blood Transfusion in cooperation with Deutsche Gesellschaft fur Transfusionsmedizin und Immunhamatologie (ISBT & DGTI)
June 26 - 1, 2010 | Berlin, Germany

  • Abedi MR, Wiiand ML, Doverud AC et al. Apheresis Collection of Double and Triple Platelet Doses Pathogen Inactivated with INTERCEPT Blood System™: Manufacturing and Clinical Outcome. Vox Sanguinis 2010;99 (Suppl. 1), 242.
     
  • Agildere A, Reppke S, Schäfer U et al. Implementation of 5 Buffy Coat Pooled Platelet Units Treated With INTERCEPT Blood System: Experience at the DRK Blutspendedienst in Baden-Baden. Vox Sanguinis 2010;99 (Suppl. 1), 257.
     
  • Baumann-Baretti B, Jaster G, Brys B et al. Production of Two Therapeutic Platelet Components Pathogen Inactivated with a Single INTERCEPT Dual Storage (DS) Processing Set from Double- and Triple Dose Apheresis by MCS+® and Trima 5.1 Accel®. Vox Sanguinis 2010;99 (Suppl. 1), 248.
     
  • De Valensart N, Rapaille A, Meuter R et al. Plasma from Whole Blood Treated with INTERCEPT Platelet Processing Set. Vox Sanguinis 2010;99 (Suppl. 1), 240.
    [Poster PDF]
     
  • Garraud O, Chavarin P, de Putter C et al. Validation of the INTERCEPT Blood System™ for Pathogen Inactivation of Apheresis Plasma at a Regional Center (EFS-Auvergne Loire).
    Vox Sanguinis 2010;99 (Suppl. 1), 253.
    [Poster PDF]
     
  • Garraud O, Cognasse F, Chavarin P et al. Validation of INTERCEPT™ Pathogen Inactivation Process for Platelet Components Suspended in a Mixture of Plasma and SSP+ at a Regional Center (EFS Auvergne Loire In France). Vox Sanguinis 2010;99 (Suppl. 1), 253.
     
  • Henschler R, Janetzko K, Erterek B et al.  Characterization of Red Blood Cell Concentrates Treated with the S-303 Pathogen Inactivation System and Stored in Saline Adenine Glucose-Mannitol (SAGM) Solution.
     
  • Ipsevich F, De Rosa A, Miceli M et al. Use of Pathogen-Inactivated Apheresis and Buffy-Coat Pool Platelet Concentrates: Evaluation Program of Transfusional Quality and Efficacy. Vox Sanguinis 2010;99 (Suppl. 1), 257.
     
  • Isola H, Kientz D, Wiesel ML et al. The Use Of TACSI® System: Effect Of Automation On Routine Production Of Pooled Platelet Concentrates For Pathogen Inactivation At The EFS-Alsace. Vox Sanguinis 2010;99 (Suppl. 1), 212.
     
  • Jessen M, Steinle I, Braun M et al. Validation of Apheresis Platelet Components Treated with INTERCEPT™ Pathogen Inactivation at the Institute Schleswig German Red Cross North. Vox Sanguinis 2010;99 (Suppl. 1), 258.
     
  • Knutson F,  Lejskog K, Löf H. A Feasibility Study with the TACSI™ Device Producing 2 Doses of Platelets Stored for 7 Days with the Use of One INTERCEPT™ Pathogen Inactivation Kit. Vox Sanguinis 2010;99 (Suppl. 1), 202.
     
  • Lehmann C, Rummler S, Kummer C et al. Pathogen Inactivation Of Single Donor Plasma. Vox Sanguinis 2010;99 (Suppl. 1), 242.
     
  • Lozano M, Knutson N, Tardivel R.  A Multi-Center Study of Therapeutic Efficacy and Safety of Platelet Components Prepared with Pathogen Inactivation (INTERCEPT) Stored for 6 or 7 Days Prior to Transfusion.
     
  • Lizardo B, Braukmann K, Lüdtke I et al. Implementation of 5 Buffy Coat Pooled Platelet Components Treated with the INTERCEPT Blood System™: Experience in German Red Cross Blood Donation Service Nord. Vox Sanguinis 2010;99 (Suppl. 1), 258 .
    [Poster PDF]

  • Malvaux N, Courrier P, Collart M. Validation of Pooled Buffy Coat Platelet Components Suspended in a Mixture of Plasma and SSP+ Treated with INTERCEPT™ Pathogen Inactivation at Center for Transfusion Services (CTS) in Luxembourg. Vox Sanguinis 2010;99 (Suppl. 1), 253.
    [Poster PDF]
     
  • Massard S, Civadier C, Sailliol A et al. Routine Production of Apheresis Plasma Pathogen Inactivated Using the INTERCEPT Blood System™: Preservation of Plasma Quality. Vox Sanguinis 2010;99 (Suppl. 1), 258.
    [Poster PDF]
     
  • Müller-Steinhardt M, Janetzko M. Evaluation of Apheresis Platelet Concentrates Treated with INTERCEPT™ Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 252.
     
  • Müller-Steinhardt M, Janetzko K. Evaluation of Apheresis Plasma Treated with INTERCEPT™ Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 251.
     
  • Osselaer JC, De Coene B, Thonet MC et al. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components Stored for More Than 5 Days: A Nine Year Hemovigilance Survey. Vox Sanguinis 2010;99 (Suppl. 1), 433.
    [Poster PDF]
     
  • Osselaer JC, Defoin L, Doyen C et al. INTERCEPT for Pathogen Inactivation (PI) in Platelet Concentrates (PC) Effectively Prevents Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD). Vox Sanguinis 2010;99 (Suppl. 1), 428.
    [Poster PDF]
     
  • Pajares Herraiz AL, Rodriguez AP, Diaz VI et al. Modification of the INTERCEPT Processing Set for Plasma: Easier and Faster Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 242.
     
  • Saldado W, Le Yondre F, Perrault MP et al. Process Validation of the INTERCEPT Blood System™ for Pathogen Inactivation of Apheresis Plasma at a Regional Center (EFS-Centre Atlantique). Vox Sanguinis 2010;99 (Suppl. 1), 254.
International Conference on Emerging Infectious Diseases (ICEID)
July 11 - 14, 2010 | Atlanta, Georgia, USA
  • Sawyer L, Higgs S, Tsetsarkin K et al.  Inactivation of Transfusion-Transmitted Vector-Borne Pathogens.
    [Poster PDF]

1st International Workshop on XMRV

  • Mikovits JA, Hagen K, Liu W et al.  Inactivation of XMRV in Platelet and RBC Components Prepared with The INTERCEPT Blood System.

2010 AABB Annual Meeting & CTTXPO
October 9-12, 2010 | Baltimore, Maryland, USA

  • Cancelas JA, Rugg N, Dumont LJ et al.  Comprehensive Evaluation of a New Process for S-303 Pathogen-Inactivation of Red Blood Cells.
     
  • Girona-Llobera E, Galmés-Trueba A, Jimenez-Marco T et al.  Platelet Pathogen Inactivation Improve Platelet Components Management and Lowering the Production Cost Associated with Expiration.  Transfusion 2010; 50 (Supplement) :52A.
    [Abstract PDF]
     
  • Henschler R, Janetzko K, Erterek B et al.  Evaluation of the S-303 Pathogen Inactivation (PI) System with RBC Components Using US and EU Processing Practices.
    [Poster PDF]
     
  • Lozano M, Knutson F, Tardivel R et al.  Frequency of Prophylactic Transfusion Failure: A Novel Outcome To Evaluate Platelet Components Stored More Than 5 Days.  Transfusion 2010; 50 (Supplement) :25A.
    [Abstract PDF]
     
  • Mikovits J, Hagen K, Sadowski C et al. Inactivation of XMRV by the INTERCEPT Blood SystemTM in Platelet Concentrates.
    [Poster PDF]
     
  • North AK, Henschler R, Geisen C et al.  Evaluation of Naturally Occurring Antibodies To Pathogen Inactivated Red Blood Cells.
Untitled Document